September 20, 2023 12:52 PM EDT
Pharma
FDA+

FDA un­der­scores qual­i­ty, safe­ty con­cerns with Intar­cia’s di­a­betes treat­ment ahead of ad­comm

Lia DeGroot

Af­ter be­ing re­ject­ed twice by the FDA in the past six years, Intar­cia Ther­a­peu­tics’ drug-de­vice prod­uct to treat type 2 di­a­betes will be the sub­ject …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ali­gos’ tri­al for oral MASH treat­ment suc­ceeds, but place­bo group shows odd trend

Lasker Award goes to three sci­en­tists who pi­o­neered re­search be­hind GLP-1 drugs

FDA in­spec­tors dis­cov­er trucks car­ry­ing torn-up records leav­ing In­di­an gener­ics fac­to­ry

Ex­clu­sive: Flag­ship-backed Va­lo Health los­es in­ter­im CEO ahead of key Phase 2 read­out

Stem cell start­up spun out of George Church’s lab rais­es $75M

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times